Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 243

1.

The Personalized Parkinson Project: examining disease progression through broad biomarkers in early Parkinson's disease.

Bloem BR, Marks WJ Jr, Silva de Lima AL, Kuijf ML, van Laar T, Jacobs BPF, Verbeek MM, Helmich RC, van de Warrenburg BP, Evers LJW, intHout J, van de Zande T, Snyder TM, Kapur R, Meinders MJ.

BMC Neurol. 2019 Jul 17;19(1):160. doi: 10.1186/s12883-019-1394-3.

2.

Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis.

Bridel C, van Wieringen WN, Zetterberg H, Tijms BM, Teunissen CE; and the NFL Group, Alvarez-Cermeño JC, Andreasson U, Axelsson M, Bäckström DC, Bartos A, Bjerke M, Blennow K, Boxer A, Brundin L, Burman J, Christensen T, Fialová L, Forsgren L, Frederiksen JL, Gisslén M, Gray E, Gunnarsson M, Hall S, Hansson O, Herbert MK, Jakobsson J, Jessen-Krut J, Janelidze S, Johannsson G, Jonsson M, Kappos L, Khademi M, Khalil M, Kuhle J, Landén M, Leinonen V, Logroscino G, Lu CH, Lycke J, Magdalinou NK, Malaspina A, Mattsson N, Meeter LH, Mehta SR, Modvig S, Olsson T, Paterson RW, Pérez-Santiago J, Piehl F, Pijnenburg YAL, Pyykkö OT, Ragnarsson O, Rojas JC, Romme Christensen J, Sandberg L, Scherling CS, Schott JM, Sellebjerg FT, Simone IL, Skillbäck T, Stilund M, Sundström P, Svenningsson A, Tortelli R, Tortorella C, Trentini A, Troiano M, Turner MR, van Swieten JC, Vågberg M, Verbeek MM, Villar LM, Visser PJ, Wallin A, Weiss A, Wikkelsø C, Wild EJ.

JAMA Neurol. 2019 Jun 17. doi: 10.1001/jamaneurol.2019.1534. [Epub ahead of print]

PMID:
31206160
3.

Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study.

Lleó A, Alcolea D, Martínez-Lage P, Scheltens P, Parnetti L, Poirier J, Simonsen AH, Verbeek MM, Rosa-Neto P, Slot RER, Tainta M, Izaguirre A, Reijs BLR, Farotti L, Tsolaki M, Vandenbergue R, Freund-Levi Y, Verhey FRJ, Clarimón J, Fortea J, Frolich L, Santana I, Molinuevo JL, Lehmann S, Visser PJ, Teunissen CE, Zetterberg H, Blennow K.

Alzheimers Dement. 2019 Jun;15(6):742-753. doi: 10.1016/j.jalz.2019.01.015. Epub 2019 Apr 6.

PMID:
30967340
4.

Serum NFL discriminates Parkinson disease from atypical parkinsonisms.

Marques TM, van Rumund A, Oeckl P, Kuiperij HB, Esselink RAJ, Bloem BR, Otto M, Verbeek MM.

Neurology. 2019 Mar 26;92(13):e1479-e1486. doi: 10.1212/WNL.0000000000007179. Epub 2019 Feb 27.

PMID:
30814322
5.

α-Synuclein real-time quaking-induced conversion in the cerebrospinal fluid of uncertain cases of parkinsonism.

van Rumund A, Green AJE, Fairfoul G, Esselink RAJ, Bloem BR, Verbeek MM.

Ann Neurol. 2019 May;85(5):777-781. doi: 10.1002/ana.25447. Epub 2019 Mar 25.

6.

Valuing biomarker diagnostics for dementia care: enhancing the reflection of patients, their care-givers and members of the wider public.

van der Burg S, Schreuder FHBM, Klijn CJM, Verbeek MM.

Med Health Care Philos. 2019 Jan 24. doi: 10.1007/s11019-018-09883-2. [Epub ahead of print]

PMID:
30680512
7.

Cerebrospinal Fluid Galectin-1 Levels Discriminate Patients with Parkinsonism from Controls.

Marques TM, van Rumund A, Bruinsma IB, Wessels HJCT, Gloerich J, Esselink RAJ, Bloem BR, Kuiperij HB, Verbeek MM.

Mol Neurobiol. 2019 Jul;56(7):5067-5074. doi: 10.1007/s12035-018-1426-9. Epub 2018 Nov 21.

PMID:
30465235
8.

C-Reactive Protein, Plasma Amyloid-β Levels, and Their Interaction With Magnetic Resonance Imaging Markers.

Hilal S, Ikram MA, Verbeek MM, Franco OH, Stoops E, Vanderstichele H, Niessen WJ, Vernooij MW.

Stroke. 2018 Nov;49(11):2692-2698. doi: 10.1161/STROKEAHA.118.022317.

PMID:
30355213
9.

Quantitative Genetics Validates Previous Genetic Variants and Identifies Novel Genetic Players Influencing Alzheimer's Disease Cerebrospinal Fluid Biomarkers.

Ramos de Matos M, Ferreira C, Herukka SK, Soininen H, Janeiro A, Santana I, Baldeiras I, Almeida MR, Lleó A, Dols-Icardo O, Alcolea D, Benussi L, Binetti G, Paterlini A, Ghidoni R, Nacmias B, Meulenbroek O, van Waalwijk van Doorn LJC, Kuiperi HBJ, Hausner L, Waldemar G, Simonsen AH, Tsolaki M, Gkatzima O, Resende de Oliveira C, Verbeek MM, Clarimon J, Hiltunen M, de Mendonça A, Martins M.

J Alzheimers Dis. 2018;66(2):639-652. doi: 10.3233/JAD-180512.

PMID:
30320580
10.

Plasma amyloid-β levels, cerebral atrophy and risk of dementia: a population-based study.

Hilal S, Wolters FJ, Verbeek MM, Vanderstichele H, Ikram MK, Stoops E, Ikram MA, Vernooij MW.

Alzheimers Res Ther. 2018 Jun 30;10(1):63. doi: 10.1186/s13195-018-0395-6.

11.

The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review.

Hansson O, Mikulskis A, Fagan AM, Teunissen C, Zetterberg H, Vanderstichele H, Molinuevo JL, Shaw LM, Vandijck M, Verbeek MM, Savage M, Mattsson N, Lewczuk P, Batrla R, Rutz S, Dean RA, Blennow K.

Alzheimers Dement. 2018 Oct;14(10):1313-1333. doi: 10.1016/j.jalz.2018.05.008. Epub 2018 Jun 23. Review.

PMID:
29940161
12.

Correction to: Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline.

Bos I, Verhey FR, Ramakers IHGB, Jacobs HIL, Soininen H, Freund-Levi Y, Hampel H, Tsolaki M, Wallin ÅK, van Buchem MA, Oleksik A, Verbeek MM, Rikkert MO, van der Flier WM, Scheltens P, Aalten P, Visser PJ, Vos SJB.

Alzheimers Res Ther. 2018 Jun 20;10(1):56. doi: 10.1186/s13195-018-0391-x.

13.

Parkinson's Disease Diagnostic Observations (PADDO): study rationale and design of a prospective cohort study for early differentiation of parkinsonism.

van Rumund A, Aerts MB, Esselink RAJ, Meijer FJA, Verbeek MM, Bloem BR.

BMC Neurol. 2018 May 16;18(1):69. doi: 10.1186/s12883-018-1072-x.

14.

Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease.

Mattsson N, Groot C, Jansen WJ, Landau SM, Villemagne VL, Engelborghs S, Mintun MM, Lleo A, Molinuevo JL, Jagust WJ, Frisoni GB, Ivanoiu A, Chételat G, Resende de Oliveira C, Rodrigue KM, Kornhuber J, Wallin A, Klimkowicz-Mrowiec A, Kandimalla R, Popp J, Aalten PP, Aarsland D, Alcolea D, Almdahl IS, Baldeiras I, van Buchem MA, Cavedo E, Chen K, Cohen AD, Förster S, Fortea J, Frederiksen KS, Freund-Levi Y, Gill KD, Gkatzima O, Grimmer T, Hampel H, Herukka SK, Johannsen P, van Laere K, de Leon MJ, Maier W, Marcusson J, Meulenbroek O, Møllergård HM, Morris JC, Mroczko B, Nordlund A, Prabhakar S, Peters O, Rami L, Rodríguez-Rodríguez E, Roe CM, Rüther E, Santana I, Schröder J, Seo SW, Soininen H, Spiru L, Stomrud E, Struyfs H, Teunissen CE, Verhey FRJ, Vos SJB, van Waalwijk van Doorn LJC, Waldemar G, Wallin ÅK, Wiltfang J, Vandenberghe R, Brooks DJ, Fladby T, Rowe CC, Drzezga A, Verbeek MM, Sarazin M, Wolk DA, Fleisher AS, Klunk WE, Na DL, Sánchez-Juan P, Lee DY, Nordberg A, Tsolaki M, Camus V, Rinne JO, Fagan AM, Zetterberg H, Blennow K, Rabinovici GD, Hansson O, van Berckel BNM, van der Flier WM, Scheltens P, Visser PJ, Ossenkoppele R.

Alzheimers Dement. 2018 Jul;14(7):913-924. doi: 10.1016/j.jalz.2018.02.009. Epub 2018 Mar 28.

PMID:
29601787
15.

White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation.

Teunissen CE, Otto M, Engelborghs S, Herukka SK, Lehmann S, Lewczuk P, Lleó A, Perret-Liaudet A, Tumani H, Turner MR, Verbeek MM, Wiltfang J, Zetterberg H, Parnetti L, Blennow K.

Alzheimers Res Ther. 2018 Mar 15;10(1):30. doi: 10.1186/s13195-018-0359-x. Review.

16.

Plasma Aβ (Amyloid-β) Levels and Severity and Progression of Small Vessel Disease.

van Leijsen EMC, Kuiperij HB, Kersten I, Bergkamp MI, van Uden IWM, Vanderstichele H, Stoops E, Claassen JAHR, van Dijk EJ, de Leeuw FE, Verbeek MM.

Stroke. 2018 Apr;49(4):884-890. doi: 10.1161/STROKEAHA.117.019810. Epub 2018 Mar 14.

PMID:
29540613
17.

Cerebral tryptophan metabolism and outcome of tuberculous meningitis: an observational cohort study.

van Laarhoven A, Dian S, Aguirre-Gamboa R, Avila-Pacheco J, Ricaño-Ponce I, Ruesen C, Annisa J, Koeken VACM, Chaidir L, Li Y, Achmad TH, Joosten LAB, Notebaart RA, Ruslami R, Netea MG, Verbeek MM, Alisjahbana B, Kumar V, Clish CB, Ganiem AR, van Crevel R.

Lancet Infect Dis. 2018 May;18(5):526-535. doi: 10.1016/S1473-3099(18)30053-7. Epub 2018 Feb 3.

PMID:
29395996
18.

Mutations in CYB561 Causing a Novel Orthostatic Hypotension Syndrome.

van den Berg MP, Almomani R, Biaggioni I, van Faassen M, van der Harst P, Silljé HHW, Mateo Leach I, Hemmelder MH, Navis G, Luijckx GJ, de Brouwer APM, Venselaar H, Verbeek MM, van der Zwaag PA, Jongbloed JDH, van Tintelen JP, Wevers RA, Kema IP.

Circ Res. 2018 Mar 16;122(6):846-854. doi: 10.1161/CIRCRESAHA.117.311949. Epub 2018 Jan 17.

19.

Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline.

Bos I, Verhey FR, Ramakers IHGB, Jacobs HIL, Soininen H, Freund-Levi Y, Hampel H, Tsolaki M, Wallin ÅK, van Buchem MA, Oleksik A, Verbeek MM, Olde Rikkert M, van der Flier WM, Scheltens P, Aalten P, Visser PJ, Vos SJB.

Alzheimers Res Ther. 2017 Dec 29;9(1):101. doi: 10.1186/s13195-017-0328-9. Erratum in: Alzheimers Res Ther. 2018 Jun 20;10(1):56.

20.

Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis.

Feneberg E, Oeckl P, Steinacker P, Verde F, Barro C, Van Damme P, Gray E, Grosskreutz J, Jardel C, Kuhle J, Koerner S, Lamari F, Amador MDM, Mayer B, Morelli C, Muckova P, Petri S, Poesen K, Raaphorst J, Salachas F, Silani V, Stubendorff B, Turner MR, Verbeek MM, Weishaupt JH, Weydt P, Ludolph AC, Otto M.

Neurology. 2018 Jan 2;90(1):e22-e30. doi: 10.1212/WNL.0000000000004761. Epub 2017 Dec 6.

PMID:
29212830
21.

Regulator of oligodendrocyte maturation, miR-219, a potential biomarker for MS.

Bruinsma IB, van Dijk M, Bridel C, van de Lisdonk T, Haverkort SQ, Runia TF, Steinman L, Hintzen RQ, Killestein J, Verbeek MM, Teunissen CE, de Jong BA.

J Neuroinflammation. 2017 Dec 4;14(1):235. doi: 10.1186/s12974-017-1006-3.

22.

Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia.

Jansen WJ, Ossenkoppele R, Tijms BM, Fagan AM, Hansson O, Klunk WE, van der Flier WM, Villemagne VL, Frisoni GB, Fleisher AS, Lleó A, Mintun MA, Wallin A, Engelborghs S, Na DL, Chételat G, Molinuevo JL, Landau SM, Mattsson N, Kornhuber J, Sabri O, Rowe CC, Parnetti L, Popp J, Fladby T, Jagust WJ, Aalten P, Lee DY, Vandenberghe R, Resende de Oliveira C, Kapaki E, Froelich L, Ivanoiu A, Gabryelewicz T, Verbeek MM, Sanchez-Juan P, Hildebrandt H, Camus V, Zboch M, Brooks DJ, Drzezga A, Rinne JO, Newberg A, de Mendonça A, Sarazin M, Rabinovici GD, Madsen K, Kramberger MG, Nordberg A, Mok V, Mroczko B, Wolk DA, Meyer PT, Tsolaki M, Scheltens P, Verhey FRJ, Visser PJ; Amyloid Biomarker Study Group, Aarsland D, Alcolea D, Alexander M, Almdahl IS, Arnold SE, Baldeiras I, Barthel H, van Berckel BNM, Blennow K, van Buchem MA, Cavedo E, Chen K, Chipi E, Cohen AD, Förster S, Fortea J, Frederiksen KS, Freund-Levi Y, Gkatzima O, Gordon MF, Grimmer T, Hampel H, Hausner L, Hellwig S, Herukka SK, Johannsen P, Klimkowicz-Mrowiec A, Köhler S, Koglin N, van Laere K, de Leon M, Lisetti V, Maier W, Marcusson J, Meulenbroek O, Møllergård HM, Morris JC, Nordlund A, Novak GP, Paraskevas GP, Perera G, Peters O, Ramakers IHGB, Rami L, Rodríguez-Rodríguez E, Roe CM, Rot U, Rüther E, Santana I, Schröder J, Seo SW, Soininen H, Spiru L, Stomrud E, Struyfs H, Teunissen CE, Vos SJB, van Waalwijk van Doorn LJC, Waldemar G, Wallin ÅK, Wiltfang J, Zetterberg H.

JAMA Psychiatry. 2018 Jan 1;75(1):84-95. doi: 10.1001/jamapsychiatry.2017.3391. Erratum in: JAMA Psychiatry. 2018 Mar 1;75(3):303.

23.

Biomarkers in cerebrospinal fluid for synucleinopathies, tauopathies, and other neurodegenerative disorders.

Marques TM, Van Rumund A, Kuiperij HB, Verbeek MM.

Handb Clin Neurol. 2017;146:99-113. doi: 10.1016/B978-0-12-804279-3.00007-1. Review.

PMID:
29110782
24.

Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry.

Lewczuk P, Riederer P, O'Bryant SE, Verbeek MM, Dubois B, Visser PJ, Jellinger KA, Engelborghs S, Ramirez A, Parnetti L, Jack CR Jr, Teunissen CE, Hampel H, Lleó A, Jessen F, Glodzik L, de Leon MJ, Fagan AM, Molinuevo JL, Jansen WJ, Winblad B, Shaw LM, Andreasson U, Otto M, Mollenhauer B, Wiltfang J, Turner MR, Zerr I, Handels R, Thompson AG, Johansson G, Ermann N, Trojanowski JQ, Karaca I, Wagner H, Oeckl P, van Waalwijk van Doorn L, Bjerke M, Kapogiannis D, Kuiperij HB, Farotti L, Li Y, Gordon BA, Epelbaum S, Vos SJB, Klijn CJM, Van Nostrand WE, Minguillon C, Schmitz M, Gallo C, Lopez Mato A, Thibaut F, Lista S, Alcolea D, Zetterberg H, Blennow K, Kornhuber J; Members of the WFSBP Task Force Working on this Topic: Peter Riederer, Carla Gallo, Dimitrios Kapogiannis, Andrea Lopez Mato, Florence Thibaut.

World J Biol Psychiatry. 2018 Jun;19(4):244-328. doi: 10.1080/15622975.2017.1375556. Epub 2017 Oct 27. Review.

25.

Plasma Amyloid-β Levels, Cerebral Small Vessel Disease, and Cognition: The Rotterdam Study.

Hilal S, Akoudad S, van Duijn CM, Niessen WJ, Verbeek MM, Vanderstichele H, Stoops E, Ikram MA, Vernooij MW.

J Alzheimers Dis. 2017;60(3):977-987. doi: 10.3233/JAD-170458.

PMID:
28984600
26.

Animal models of cerebral amyloid angiopathy.

Jäkel L, Van Nostrand WE, Nicoll JAR, Werring DJ, Verbeek MM.

Clin Sci (Lond). 2017 Sep 28;131(19):2469-2488. doi: 10.1042/CS20170033. Print 2017 Oct 15. Review.

PMID:
28963121
27.

The increasing impact of cerebral amyloid angiopathy: essential new insights for clinical practice.

Banerjee G, Carare R, Cordonnier C, Greenberg SM, Schneider JA, Smith EE, Buchem MV, Grond JV, Verbeek MM, Werring DJ.

J Neurol Neurosurg Psychiatry. 2017 Nov;88(11):982-994. doi: 10.1136/jnnp-2016-314697. Epub 2017 Aug 26. Review.

28.

Multicenter Analytical Validation of Aβ40 Immunoassays.

van Waalwijk van Doorn LJC, Kulic L, Koel-Simmelink MJA, Kuiperij HB, Versleijen AAM, Struyfs H, Twaalfhoven HAM, Fourier A, Engelborghs S, Perret-Liaudet A, Lehmann S, Verbeek MM, Vanmechelen EJM, Teunissen CE.

Front Neurol. 2017 Jul 3;8:310. doi: 10.3389/fneur.2017.00310. eCollection 2017.

29.

Upstream SLC2A1 translation initiation causes GLUT1 deficiency syndrome.

Willemsen MA, Vissers LE, Verbeek MM, van Bon BW, Geuer S, Gilissen C, Klepper J, Kwint MP, Leen WG, Pennings M, Wevers RA, Veltman JA, Kamsteeg EJ.

Eur J Hum Genet. 2017 Jun;25(6):771-774. doi: 10.1038/ejhg.2017.45. Epub 2017 Apr 5.

30.

Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes.

van Waalwijk van Doorn LJ, Gispert JD, Kuiperij HB, Claassen JA, Arighi A, Baldeiras I, Blennow K, Bozzali M, Castelo-Branco M, Cavedo E, Emek-Savaş DD, Eren E, Eusebi P, Farotti L, Fenoglio C, Ormaechea JF, Freund-Levi Y, Frisoni GB, Galimberti D, Genc S, Greco V, Hampel H, Herukka SK, Liu Y, Lladó A, Lleó A, Nobili FM, Oguz KK, Parnetti L, Pereira J, Picco A, Pikkarainen M, de Oliveira CR, Saka E, Salvadori N, Sanchez-Valle R, Santana I, Scarpini E, Scheltens P, Soininen H, Tarducci R, Teunissen C, Tsolaki M, Urbani A, Vilaplana E, Visser PJ, Wallin AK, Yener G, Molinuevo JL, Meulenbroek O, Verbeek MM.

J Alzheimers Dis. 2017;56(2):543-555. doi: 10.3233/JAD-160668.

PMID:
28059783
31.

β-Amyloid in CSF: Biomarker for preclinical cerebral amyloid angiopathy.

van Etten ES, Verbeek MM, van der Grond J, Zielman R, van Rooden S, van Zwet EW, van Opstal AM, Haan J, Greenberg SM, van Buchem MA, Wermer MJ, Terwindt GM.

Neurology. 2017 Jan 10;88(2):169-176. doi: 10.1212/WNL.0000000000003486. Epub 2016 Nov 30.

32.

Soluble TLR2 and 4 concentrations in cerebrospinal fluid in HIV/SIV-related neuropathological conditions.

Mothapo KM, Ten Oever J, Koopmans P, Stelma FF, Burm S, Bajramovic J, Verbeek MM, Rikkert MGO, Netea MG, Koopman G, van der Ven AJ.

J Neurovirol. 2017 Apr;23(2):250-259. doi: 10.1007/s13365-016-0495-7. Epub 2016 Nov 23.

PMID:
27882497
33.

MicroRNAs in Cerebrospinal Fluid as Potential Biomarkers for Parkinson's Disease and Multiple System Atrophy.

Marques TM, Kuiperij HB, Bruinsma IB, van Rumund A, Aerts MB, Esselink RAJ, Bloem BR, Verbeek MM.

Mol Neurobiol. 2017 Dec;54(10):7736-7745. doi: 10.1007/s12035-016-0253-0. Epub 2016 Nov 14.

34.

Limitations of the hCMEC/D3 cell line as a model for Aβ clearance by the human blood-brain barrier.

Biemans EALM, Jäkel L, de Waal RMW, Kuiperij HB, Verbeek MM.

J Neurosci Res. 2017 Jul;95(7):1513-1522. doi: 10.1002/jnr.23964. Epub 2016 Oct 11.

35.

White Matter Hyperintensities Potentiate Hippocampal Volume Reduction in Non-Demented Older Individuals with Abnormal Amyloid-β.

Freeze WM, Jacobs HI, Gronenschild EH, Jansen JF, Burgmans S, Aalten P, Clerx L, Vos SJ, van Buchem MA, Barkhof F, van der Flier WM, Verbeek MM, Rikkert MO, Backes WH, Verhey FR; LeARN project.

J Alzheimers Dis. 2017;55(1):333-342.

PMID:
27662299
36.

Tau Rather than TDP-43 Proteins are Potential Cerebrospinal Fluid Biomarkers for Frontotemporal Lobar Degeneration Subtypes: A Pilot Study.

Kuiperij HB, Versleijen AA, Beenes M, Verwey NA, Benussi L, Paterlini A, Binetti G, Teunissen CE, Raaphorst J, Schelhaas HJ, Küsters B, Pijnenburg YA, Ghidoni R, Verbeek MM.

J Alzheimers Dis. 2017;55(2):585-595.

PMID:
27662293
37.

Nigrosome-1 on Susceptibility Weighted Imaging to Differentiate Parkinson's Disease From Atypical Parkinsonism: An In Vivo and Ex Vivo Pilot Study.

Meijer FJ, Steens SC, van Rumund A, van Cappellen van Walsum AM, Küsters B, Esselink RA, Verbeek MM, Bloem BR, Goraj B.

Pol J Radiol. 2016 Aug 3;81:363-9. doi: 10.12659/PJR.897090. eCollection 2016.

38.

Increased CSF biomarkers of angiogenesis in Parkinson disease.

Lattanzi S, Silvestrini M, Verbeek MM, Mollenhauer B, Lindqvist D, Janelidze S, Hansson O.

Neurology. 2016 May 3;86(18):1747-8. doi: 10.1212/WNL.0000000000002667. No abstract available.

PMID:
27164652
39.

CSF d-serine concentrations are similar in Alzheimer's disease, other dementias, and elderly controls.

Biemans EA, Verhoeven-Duif NM, Gerrits J, Claassen JA, Kuiperij HB, Verbeek MM.

Neurobiol Aging. 2016 Jun;42:213-6. doi: 10.1016/j.neurobiolaging.2016.03.017. Epub 2016 Mar 23.

PMID:
27143438
40.

Validation of microRNAs in Cerebrospinal Fluid as Biomarkers for Different Forms of Dementia in a Multicenter Study.

Müller M, Kuiperij HB, Versleijen AA, Chiasserini D, Farotti L, Baschieri F, Parnetti L, Struyfs H, De Roeck N, Luyckx J, Engelborghs S, Claassen JA, Verbeek MM.

J Alzheimers Dis. 2016 Apr 16;52(4):1321-33. doi: 10.3233/JAD-160038.

PMID:
27104900
41.

Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics.

Lelental N, Brandner S, Kofanova O, Blennow K, Zetterberg H, Andreasson U, Engelborghs S, Mroczko B, Gabryelewicz T, Teunissen C, Mollenhauer B, Parnetti L, Chiasserini D, Molinuevo JL, Perret-Liaudet A, Verbeek MM, Andreasen N, Brosseron F, Bahl JM, Herukka SK, Hausner L, Frölich L, Labonte A, Poirier J, Miller AM, Zilka N, Kovacech B, Urbani A, Suardi S, Oliveira C, Baldeiras I, Dubois B, Rot U, Lehmann S, Skinningsrud A, Betsou F, Wiltfang J, Gkatzima O, Winblad B, Buchfelder M, Kornhuber J, Lewczuk P.

J Alzheimers Dis. 2016 Mar 1;52(1):51-64. doi: 10.3233/JAD-150883.

PMID:
26967210
42.

Hourly analysis of cerebrospinal fluid glucose shows large diurnal fluctuations.

Verbeek MM, Leen WG, Willemsen MA, Slats D, Claassen JA.

J Cereb Blood Flow Metab. 2016 May;36(5):899-902. doi: 10.1177/0271678X16637612. Epub 2016 Mar 4.

43.

Validation of soluble amyloid-β precursor protein assays as diagnostic CSF biomarkers for neurodegenerative diseases.

van Waalwijk van Doorn LJ, Koel-Simmelink MJ, Haußmann U, Klafki H, Struyfs H, Linning P, Knölker HJ, Twaalfhoven H, Kuiperij HB, Engelborghs S, Scheltens P, Verbeek MM, Vanmechelen E, Wiltfang J, Teunissen CE.

J Neurochem. 2016 Apr;137(1):112-21. doi: 10.1111/jnc.13527. Epub 2016 Jan 24.

44.

A multifunctional ELISA to measure oxidised proteins: oxPin1 in Alzheimer's brain as an example.

Herbert MK, Verbeek MM, Küsters B, Kuiperij HB.

BBA Clin. 2015 Apr 30;4:1-6. eCollection 2015 Dec.

45.

The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases.

Reijs BL, Teunissen CE, Goncharenko N, Betsou F, Blennow K, Baldeiras I, Brosseron F, Cavedo E, Fladby T, Froelich L, Gabryelewicz T, Gurvit H, Kapaki E, Koson P, Kulic L, Lehmann S, Lewczuk P, Lleó A, Maetzler W, de Mendonça A, Miller AM, Molinuevo JL, Mollenhauer B, Parnetti L, Rot U, Schneider A, Simonsen AH, Tagliavini F, Tsolaki M, Verbeek MM, Verhey FR, Zboch M, Winblad B, Scheltens P, Zetterberg H, Visser PJ.

Front Neurol. 2015 Oct 15;6:216. doi: 10.3389/fneur.2015.00216. eCollection 2015.

46.

Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders.

Mollenhauer B, Parnetti L, Rektorova I, Kramberger MG, Pikkarainen M, Schulz-Schaeffer WJ, Aarsland D, Svenningsson P, Farotti L, Verbeek MM, Schlossmacher MG.

J Neurochem. 2016 Oct;139 Suppl 1:290-317. doi: 10.1111/jnc.13390. Epub 2016 Feb 10. Review.

47.

A Practical Guide to Immunoassay Method Validation.

Andreasson U, Perret-Liaudet A, van Waalwijk van Doorn LJ, Blennow K, Chiasserini D, Engelborghs S, Fladby T, Genc S, Kruse N, Kuiperij HB, Kulic L, Lewczuk P, Mollenhauer B, Mroczko B, Parnetti L, Vanmechelen E, Verbeek MM, Winblad B, Zetterberg H, Koel-Simmelink M, Teunissen CE.

Front Neurol. 2015 Aug 19;6:179. doi: 10.3389/fneur.2015.00179. eCollection 2015.

48.

An integrated multi-study analysis of intra-subject variability in cerebrospinal fluid amyloid-β concentrations collected by lumbar puncture and indwelling lumbar catheter.

Lucey BP, Gonzales C, Das U, Li J, Siemers ER, Slemmon JR, Bateman RJ, Huang Y, Fox GB, Claassen JA, Slats D, Verbeek MM, Tong G, Soares H, Savage MJ, Kennedy M, Forman M, Sjögren M, Margolin R, Chen X, Farlow MR, Dean RA, Waring JF.

Alzheimers Res Ther. 2015 Jul 29;7(1):53. doi: 10.1186/s13195-015-0136-z. eCollection 2015.

49.

Dickkopf-related protein 3 is a potential Aβ-associated protein in Alzheimer's Disease.

Bruggink KA, Kuiperij HB, Gloerich J, Otte-Höller I, Rozemuller AJ, Claassen JA, Küsters B, Verbeek MM.

J Neurochem. 2015 Sep;134(6):1152-62. doi: 10.1111/jnc.13216. Epub 2015 Jul 16.

50.

Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study.

Kruse N, Persson S, Alcolea D, Bahl JM, Baldeiras I, Capello E, Chiasserini D, Bocchio Chiavetto L, Emersic A, Engelborghs S, Eren E, Fladby T, Frisoni G, García-Ayllón MS, Genc S, Gkatzima O, Heegaard NH, Janeiro AM, Kováčech B, Kuiperij HB, Leitão MJ, Lleó A, Martins M, Matos M, Mollergard HM, Nobili F, Öhrfelt A, Parnetti L, de Oliveira CR, Rot U, Sáez-Valero J, Struyfs H, Tanassi JT, Taylor P, Tsolaki M, Vanmechelen E, Verbeek MM, Zilka N, Blennow K, Zetterberg H, Mollenhauer B.

Neurobiol Aging. 2015 Sep;36(9):2587-96. doi: 10.1016/j.neurobiolaging.2015.05.003. Epub 2015 May 15.

PMID:
26093515

Supplemental Content

Loading ...
Support Center